



0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

FIG. 1




CHLORTIUMIC CLEFT

FIG. 2



1/14

FIG. 3A




1. Hinc II
2. Nco I
3. BAP

T<sub>0</sub>  
FIG. 3B

T<sub>0</sub>  
FIG. 3B

2/14

FROM  
FIG. 3A



FROM  
FIG. 3A





FIG. 3B


3/14



**SUBSTITUTE SHEET**

5/14

FROM  
FIG. 4A



SUBSTITUTE SHEET





FIG. 4B

Synthetic Polylinker

6/14

FIG. 5A



1. Hinc II
2. Nco I
3. BAP

T<sub>0</sub>  
FIG. 5B

SUBSTITUTE SHEET

00220 " in the C-terminal

7/14




FIG. 5B

FIG. 6A





FIG. 6B

9/14





FIG. 7A



10/14

FIG. 7B


$T_0$

1. Hind III  
2. Isolate 268 bp  
GFAP fragment

1. Acc I  
2. Add Acc I-Hind III  
adaptors  
3. Ligase  
4. Hind III  
5. BAP

$T_0$

11/14



12/14




FIG. 8




FIG. 9

13/14




FIG. 10






FIG. 11

FIG. 12



NATIVE RAT PREPROENKEPHALIN mRNA LEVELS  
DOPAMINE TREATMENT



14/14

FIG. 13